Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Bristol-Myers Squibb Co., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Short-term debt obligations	4,509)	4,715)	3,554)	2,046)	1,078)	3,531)	6,190)	3,119)	5,467)	3,020)	2,752)	4,264)	2,132)	4,953)	7,522)	4,948)	5,065)	2,655)	1,777)	2,340)	3,585)	4,819)	3,862)
Accounts payable	4,288)	5,427)	4,002)	3,602)	3,469)	3,751)	3,539)	3,259)	2,813)	3,069)	3,194)	3,040)	2,595)	2,882)	2,944)	2,949)	2,695)	3,609)	2,972)	2,713)	2,441)	2,852)	3,069)
Other current liabilities	19,339)	17,386)	16,514)	18,126)	18,091)	15,983)	16,093)	15,884)	15,182)	14,061)	13,139)	14,586)	14,203)	13,080)	12,355)	13,971)	13,700)	12,727)	12,581)	14,027)	14,438)	15,750)	12,301)
Current liabilities	28,136)	27,528)	24,070)	23,774)	22,638)	23,265)	25,822)	22,262)	23,462)	20,150)	19,085)	21,890)	18,930)	20,915)	22,821)	21,868)	21,460)	18,991)	17,330)	19,080)	20,464)	23,421)	19,232)
Deferred income taxes	225)	247)	276)	369)	430)	461)	442)	338)	399)	751)	1,568)	2,166)	2,881)	3,034)	3,809)	4,501)	4,956)	4,931)	5,235)	5,407)	5,913)	6,157)	6,531)
Long-term debt, excluding current portion	44,469)	44,470)	46,157)	47,603)	48,674)	48,858)	49,487)	36,653)	32,137)	34,656)	35,078)	35,056)	36,966)	37,107)	37,450)	39,605)	39,677)	42,503)	44,505)	48,336)	41,364)	41,853)	42,844)
Other non-current liabilities	5,459)	4,942)	4,476)	4,469)	4,728)	4,993)	6,732)	6,421)	6,203)	5,902)	6,664)	6,590)	6,685)	6,640)	7,309)	7,334)	7,516)	7,498)	7,692)	7,776)	7,565)	7,485)	10,701)
Non-current liabilities	50,153)	49,659)	50,909)	52,441)	53,832)	54,312)	56,661)	43,412)	38,739)	41,309)	43,310)	43,812)	46,532)	46,781)	48,568)	51,440)	52,149)	54,932)	57,432)	61,519)	54,842)	55,495)	60,076)
Total liabilities	78,289)	77,187)	74,979)	76,215)	76,470)	77,577)	82,483)	65,674)	62,201)	61,459)	62,395)	65,702)	65,462)	67,696)	71,389)	73,308)	73,609)	73,923)	74,762)	80,599)	75,306)	78,916)	79,308)
Preferred stock	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Common stock	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)
Capital in excess of par value of stock	46,266)	46,133)	46,012)	46,024)	45,896)	45,766)	45,655)	45,684)	44,849)	45,299)	45,140)	45,165)	44,956)	44,375)	43,756)	44,361)	44,292)	44,064)	43,852)	44,325)	44,435)	44,444)	43,254)
Accumulated other comprehensive loss	(1,513)	(1,554)	(1,424)	(1,238)	(1,468)	(1,456)	(1,400)	(1,546)	(1,286)	(1,387)	(1,368)	(1,281)	(841)	(992)	(1,229)	(1,268)	(1,424)	(1,518)	(1,544)	(1,839)	(1,699)	(1,556)	(1,549)
Retained earnings	17,093)	16,154)	16,106)	14,912)	16,097)	16,103)	15,640)	28,766)	28,218)	27,449)	26,568)	25,503)	24,675)	24,217)	23,948)	23,820)	22,625)	22,168)	22,204)	21,281)	32,414)	31,565)	32,671)
Cost of treasury stock	(43,586)	(43,590)	(43,597)	(43,655)	(43,675)	(43,690)	(43,697)	(43,766)	(43,075)	(39,680)	(38,808)	(38,618)	(36,411)	(35,292)	(35,187)	(31,259)	(28,572)	(28,198)	(27,199)	(26,237)	(25,284)	(25,651)	(24,757)
Total BMS shareholders’ equity	18,552)	17,435)	17,389)	16,335)	17,142)	17,015)	16,490)	29,430)	28,998)	31,973)	31,824)	31,061)	32,671)	32,600)	31,580)	35,946)	37,213)	36,808)	37,605)	37,822)	50,158)	49,094)	49,911)
Noncontrolling interest	48)	54)	59)	53)	58)	54)	58)	55)	64)	57)	62)	57)	63)	61)	65)	60)	71)	66)	68)	60)	72)	66)	66)
Total equity	18,600)	17,489)	17,448)	16,388)	17,200)	17,069)	16,548)	29,485)	29,062)	32,030)	31,886)	31,118)	32,734)	32,661)	31,645)	36,006)	37,284)	36,874)	37,673)	37,882)	50,230)	49,160)	49,977)
Total liabilities and equity	96,889)	94,676)	92,427)	92,603)	93,670)	94,646)	99,031)	95,159)	91,263)	93,489)	94,281)	96,820)	98,196)	100,357)	103,034)	109,314)	110,893)	110,797)	112,435)	118,481)	125,536)	128,076)	129,285)

Short-term debt obligations: Short-term debt obligations exhibited significant volatility throughout the periods, peaking sharply at the end of March 2022, followed by a notable decrease by September 2024. This indicates fluctuating short-term financing needs or repayments occurring over time.
Accounts payable: Accounts payable displayed relatively stable fluctuations, with values generally oscillating between approximately 2,400 million and 5,400 million USD. The increasing trend towards the later part of the timeline suggests growing obligations to suppliers or vendors.
Other current liabilities: Other current liabilities showed a gradual upward trend overall, rising from around 12,300 million to over 19,300 million USD by the last reported period. This consistent increase points to expanding miscellaneous current obligations.
Current liabilities: Current liabilities fluctuated within a broad range, peaking near 28,000 million USD at the start of the timeline and demonstrating several cycles of rise and decline. The general trend suggests an increase in overall short-term financial commitments in recent quarters.
Deferred income taxes: Deferred income taxes decreased steadily, starting above 6,500 million USD and dropping below 230 million USD by the timeline’s end. This decline may reflect changes in anticipated tax liabilities or benefits recognized over time.
Long-term debt, excluding current portion: Long-term debt displayed a declining pattern overall, falling from over 42,800 million USD to approximately 44,500 million USD, with some fluctuations. Notably, a spike occurred around mid-2024, indicating possible new debt issuance or refinancing activities.
Other non-current liabilities: Other non-current liabilities generally decreased from about 10,700 million USD to approximately 5,500 million USD, with some variability. This trend suggests a reduction in long-term miscellaneous obligations over the period.
Non-current liabilities: Non-current liabilities decreased steadily from roughly 60,000 million USD to just over 50,000 million USD, with a major surge between early and mid-2024. This rise might be associated with increased long-term obligations or debt financing during that timeframe.
Total liabilities: Total liabilities showed an overall declining trend from nearly 79,300 million USD to just above 78,200 million USD, with a significant peak in early 2024. The increase in liabilities corresponds with patterns observed in both current and non-current liabilities.
Common stock and capital in excess of par value of stock: Common stock remained constant at 292 million USD, while capital in excess of par value showed a moderate increase from about 43,254 million USD to 46,266 million USD, reflecting consistent equity capital growth.
Accumulated other comprehensive loss: Accumulated other comprehensive loss showed some oscillation but generally remained negative, fluctuating between approximately -1,800 million USD to around -1,200 million USD without a clear long-term trend.
Retained earnings: Retained earnings exhibited a rise until early 2023, reaching about 28,700 million USD, followed by a considerable drop to near 15,600 million USD in early 2024 before showing a modest recovery. This pattern might indicate dividend distributions, losses, or other adjustments impacting accumulated profits.
Cost of treasury stock: The cost of treasury stock increased in absolute terms over time, moving from around -24,700 million USD to approximately -43,500 million USD, suggesting ongoing share repurchases or treasury stock accumulation.
Total BMS shareholders’ equity: Total shareholders’ equity declined noticeably from about 49,900 million USD to approximately 18,500 million USD over the timeline, with a sharp decrease around early 2024, mirrored by changes in retained earnings and other components.
Noncontrolling interest: Noncontrolling interest remained relatively stable and low, fluctuating marginally between 48 million USD and 72 million USD, indicating minimal influence from minority stakeholders.
Total equity: Total equity reflected the downward trend evident in shareholders’ equity, declining from nearly 50,000 million USD to about 18,600 million USD, with a sharp fall in early 2024 and slight recovery afterward.
Total liabilities and equity: The total combination of liabilities and equity decreased steadily from around 129,000 million USD to approximately 96,900 million USD, demonstrating an overall shrinkage in the company’s balance sheet size during the period.

Download chart

Bristol-Myers Squibb Co. (NYSE:BMY)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data